...
首页> 外文期刊>Work study >Lean readiness - the case of the European pharmaceutical manuf acturing industry
【24h】

Lean readiness - the case of the European pharmaceutical manuf acturing industry

机译:精益准备-欧洲制药业案例

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose - The purpose of this paper is to assess the quality practices of European pharmaceutical manufacturers to determine the level of readiness of this industrial sector to implement and/or sustain lean manufacturing (LM). Design/methodology/approach - An assessment framework developed by Al-Najem et al. (2013) was adapted to evaluate how ready European pharmaceutical manufacturers are to implement and/or sustain LM. Therefore, the lean readiness (LR) level of these organisations was assessed through six quality practices related to LM. These included; processes, planning and control, human resources, top management and leadership, customer relations, and supplier relations. One research question and three hypotheses were formulated and tested using a combination of descriptive statistics and non-parametric Mann-Whitney tests. Data were collected through a survey questionnaire distributed to 310 European pharmaceutical manufacturers and responded by 37 of these organisations. Findings - Overall, the results of this study indicate an inadequate level of LR for the participating firms. Simultaneously, it was concluded that factors such as company size, type of relationships with suppliers and ISO 9000 certification do not have an effect on the quality practices, and hence LR level, of European pharmaceutical manufacturing organisations. Practical implications - This study provides crucial information regarding the LR level of European pharmaceutical manufacturers, which can now be aware of the areas in their practices that require further improvement towards a successful lean journey. Simultaneously, organisations in the pharmaceutical sector that intend to implement LM can consider the results of this study and evaluate their readiness level. Managers can, therefore, refer to this research and use it as a platform to take better decisions regarding what quality aspects of their operations need to be enhanced to successfully deploy or sustain a lean strategy. Originality/value - This research is one of the very few studies that have focussed on evaluating whether the European pharmaceutical manufacturing industry is ready to successfully implement or sustain LM. Therefore, this research expands the limited existent body of knowledge of LM in this industry.
机译:目的-本文的目的是评估欧洲制药商的质量实践,以确定该行业实施和/或维持精益生产(LM)的准备程度。设计/方法/方法-Al-Najem等人开发的评估框架。 (2013)进行了评估,以评估欧洲制药商准备好实施和/或维持LM的准备程度。因此,通过与LM相关的六项质量实践评估了这些组织的精益准备水平。这些包括;流程,计划和控制,人力资源,高层管理和领导,客户关系以及供应商关系。结合描述性统计数据和非参数Mann-Whitney检验,制定并检验了一个研究问题和三个假设。通过向310家欧洲制药商分发的调查问卷收集数据,这些组织中的37家对此做出了回应。调查结果-总体而言,这项研究的结果表明,参与公司的LR水平不足。同时得出的结论是,诸如公司规模,与供应商的关系类型以及ISO 9000认证等因素对欧洲药品生产组织的质量规范和LR等级没有影响。实际意义-这项研究提供了有关欧洲药品制造商的LR等级的重要信息,这些信息现在可以了解其实践中需要进一步改进以实现成功的精益生产的领域。同时,打算实施LM的制药行业组织可以考虑本研究的结果并评估其准备水平。因此,管理人员可以参考这项研究并将其用作一个平台,以便就需要改进其运营的哪些质量方面做出更好的决策,以成功部署或维持精益战略。原创性/价值-这项研究是为数不多的专注于评估欧洲制药企业是否准备成功实施或维持LM的研究之一。因此,本研究扩展了该行业中有限的LM知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号